Oral Nicorandil for Prevention of No Reflow Phenomenon in Anterior STEMI Patients Undergoing PPCI
Status:
COMPLETED
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
Aim of the study is to Investigate the potential role of oral nicorandil in preventing the No reflow phenomenon in anterior ST-segment elevation myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention (PPCI).
Assess whether nicorandil, a potassium channel activator, can effectively enhance myocardial perfusion in this specific clinical context.
* In a randomized controlled trial study
* All recruited patients were randomized to either the treatment or control group in a ratio of 1:1 using a computer-generated randomization sequence in relation to the order of participation in the study. Patients fulfilling the inclusion criteria and consenting to participate in the study were recruited.